Esperion CMO JoAnne Foody to depart by Sept 16; transition to Senior Advisor effective Aug 5

Esperion Therapeutics, Inc.

JoAnne Foody steps down as CMO effective Aug 5; remains as Senior Advisor until Sep 16.
Severance includes 12 months salary, health coverage, prorated FY2024 bonus, extended option exercise.
Transition Agreement signed Aug 3; Foody to cooperate as Senior Advisor on requested basis.
No successor named; search for new CMO presumably underway.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

JoAnne Foody

Chief Medical Officer

ESPR · Esperion Therapeutics, Inc.

Effective: 2024-08-05
Filed: August 5, 2024, 7:59 PM ET

JoAnne Foody will be transitioning from her role as the Company’s Chief Medical Officer and that her employment with the Company will end on or before September 16, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

JoAnne Foody changed role as Chief Medical Officer at Esperion Therapeutics, Inc..

Action: transitioning
Role: Chief Medical Officer

Exact text from the filing

JoAnne Foody will be transitioning from her role as the Company’s Chief Medical Officer and that her employment with the Company will end on or before September 16, 2024

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-034766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.